Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Non-Randomized, Multicenter Phase I/II Trial of RO5424802 Given Orally to Non-Small Cell Lung Cancer Patients Who Have ALK Mutation and Who Have Failed Crizotinib Treatment

Trial Profile

An Open-Label, Non-Randomized, Multicenter Phase I/II Trial of RO5424802 Given Orally to Non-Small Cell Lung Cancer Patients Who Have ALK Mutation and Who Have Failed Crizotinib Treatment

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Jun 2019

At a glance

  • Drugs Alectinib (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Study 2
  • Sponsors Roche
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 05 Jun 2018 Results (n=207) of an exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer patients using final pooled phase II OS and safety data (NCT01801111 and NCT01871805), presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2018 Results of a pooled analysis of NP28673 and NP28761 trials (n=225) assessing the survival and safety, presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top